BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:MT-302 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of MT-302\, from ClinicalTrials.gov estimate
 s.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT05969041-2627@assetmemo.bio
DTSTAMP:20261121T004541Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:MT-302: Phase 1 readout est. (NCT05969041)
DESCRIPTION:MT-302\, phase 1.\nStudy: Study of MT-302 in Adults With Advanc
 ed or Metastatic Epithelial Tumors\nEstimated primary completion: 31 Augus
 t 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout da
 te\, and it can move.\nDrug page: https://assetmemo.bio/drug/mt-302#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT05969041
URL:https://assetmemo.bio/drug/mt-302#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
